A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC | MicrobiomeTrials← Back to trialsNCT07733180
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-09-14Est. Completion: 2028-02-28
Enrollment target: 30 participants Locations- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
- Osaka Medical and Pharmaceutical University Hospital, Takatsukishi, Osaka, Japan
- National Cancer Center Hospital, ChuoKu, Tokyo, Japan
- Osaka Keisatsu Hospital, Osaka, Japan
Other microbiome trials you might be interested in
Esophageal Squamous Cell CarcinomaImmunotherapyBiomarkers
To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemora…
Fuzhou, ChinaEst. completion Dec 2027
Locally Advanced or Metastatic Solid Tumors
This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to peopl…
Lake Success, United StatesEst. completion Feb 28, 2030